Rani Therapeutics: Oral Biologics Vision Still Has Early-Stage Risks
Source: SeekingAlpha
2025-11-05 15:22:53 ET
...
Read the full article on Seeking Alpha
For further details see:
Rani Therapeutics: Oral Biologics Vision Still Has Early-Stage Risks
Rani Therapeutics Holdings Inc.
NASDAQ: RANI
RANI Trading
-2.89% G/L:
$1.345 Last:
165,456 Volume:
$1.35 Open:
RANI Latest News
January 28, 2026 07:00:00 am
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
January 08, 2026 07:00:00 am
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
November 24, 2025 04:05:00 pm
Rani Therapeutics to Participate in the Evercore Healthcare Conference
November 06, 2025 04:30:00 pm
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
RANI Stock Data
$162,838,596
86,413,825
3.84%
30
N/A
Biotechnology & Life Sciences
Healthcare
US
San Jose
